[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365666-105":59,"doc-detail-365666-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-validation-of-plasma-metabolite-markers-for-early-lung-cancer-detection","Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection","","Early detection of lung cancer significantly improves survival, yet current screening methods have limitations. This study aimed to identify a robust panel of plasma metabolites for early-stage non-small cell lung cancer (NSCLC) diagnosis using a large, clinically diverse patient cohort. A total of 680 archived plasma samples from biopsy-confirmed NSCLC patients and controls were analyzed for discovery, while 216 samples formed an independent validation cohort. Logistic regression models based on ten metabolites achieved AUROC values around 93–94% and showed improved performance when incorporating smoking history, with validation confirming high sensitivity and specificity for early-stage detection. The findings support metabolomic biomarkers as a minimally invasive, accurate tool to complement current screening and enable earlier intervention. Further validation in more diverse populations and real-world settings is warranted.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-validation-of-plasma-metabolite-markers-for-early-lung-cancer-detection/365666/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-validation-of-plasma-metabolite-markers-for-early-lung-cancer-detection/365666.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of the study?","Question",{"text":112,"@type":113},"The study aimed to identify a robust panel of plasma metabolite markers for diagnosing early-stage non-small cell lung cancer (NSCLC).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the discovery and validation cohorts constructed?",{"text":117,"@type":113},"The discovery cohort used 680 archived plasma samples from biopsy-confirmed NSCLC patients and controls, and an independent validation cohort used 216 plasma samples.",{"name":119,"@type":110,"acceptedAnswer":120},"What model performance did the ten-metabolite logistic regression achieve?",{"text":121,"@type":113},"Using ten metabolites, logistic regression achieved AUROC values of 93.63%, 93.74%, and 93.91% for distinguishing all-stage, stage I–II, and stage I NSCLC patients from controls, respectively.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365666,1790905972,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nClinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection  \nLun Zhang 1, Jiamin Zheng 1, Rashid A. Bux 2, Jean-François Haince 2, Claudia Torres-Calzada 3, Rupasri Mandal 1,3, Andrew Maksymiuk 4,5, Guoyu Huang 2, Paramjit S. Tappia 6, Philippe Joubert 7, Christian D. Rolfo 8 and David S. Wishart 1,3,9,10,11, *  \nAcademic Editor: Amanda Iglesias  \nReceived: 26 March 2025  \nRevised: 2 May 2025  \nAccepted: 5 May 2025  \nPublished: 9 May 2025  \nCitation: Zhang, L.; Zheng, J.; Bux, R.A.; Haince, J.-F.; Torres-Calzada, C.; Mandal, R.; Maksymiuk, A.; Huang, G.; Tappia, P.S.; Joubert, P.; et al. Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection. Int. J. Mol. Sci. 2025, 26, 4519. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms26104519  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 The Metabolomics Innovation Centre, University of Alberta, Edmonton, AB T6G 2E8, Canada; [lun2@ualberta.ca](lun2@ualberta.ca) (L.Z.); [jiamin3@ualberta.ca](jiamin3@ualberta.ca) (J.Z.); [rmandal@ualberta.ca](rmandal@ualberta.ca) (R.M.)  \n2 BioMark Diagnostics Inc., Richmond, BC V6X 2W2, Canada; [rahmed@biomarkdiagnostics.com](rahmed@biomarkdiagnostics.com) (R.A.B.); [jhaince@biomarkdiagnostics.com](jhaince@biomarkdiagnostics.com) (J.-F.H.); [ghuang@biomarkdiagnostics.com](ghuang@biomarkdiagnostics.com) (G.H.)  \n3 Department of Biological Sciences, University of Alberta, Edmonton, AB T6G 2E8, Canada; [ctorresc@ualberta.ca](ctorresc@ualberta.ca)  \n4 Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada; amaksymiuk@cancercare.mb.ca  \n5 Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada  \n6 Asper Clinical Research Institute, St. Boniface Hospital, Winnipeg, MB R2H 2A6, Canada; [ptappia@sbrc.ca](ptappia@sbrc.ca)  \n[7](7 Institut Universitaire de Cardiologie et de Pneumologie de Qu)[ Institut Universitaire de Cardiologie et de Pneumologie de Qu](7 Institut Universitaire de Cardiologie et de Pneumologie de Qu)é[bec-Universit](bec-Universit)é [Laval](Laval), [Quebec](Quebec), [QC G1V 4G5](QC G1V 4G5), Canada; [philippe.joubert@criucpq.ulaval.ca](philippe.joubert@criucpq.ulaval.ca)  \n8 Department of Internal Medicine, Division of Medical Oncology, The Arthur G. James Comprehensive Cancer Center, 460 W 12th Avenue, Columbus, OH 43210, USA; [christian.rolfo@osumc.edu](christian.rolfo@osumc.edu)  \n9 Department of Computing Science, University of Alberta, Edmonton, AB T6G 2E8, Canada  \n10 Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2B7, Canada  \n11 Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada  \n* Correspondence: [dwishart@ualberta.ca](dwishart@ualberta.ca)  \nAbstract: Early detection of lung cancer significantly improves survival, yet current screening methods have limitations. This study aimed to identify a robust panel of plasma metabolites for early-stage non-small cell lung cancer (NSCLC) diagnosis using a large, clinically diverse patient cohort. A total of 680 archived plasma samples from biopsy-confirmed NSCLC patients and controls (including healthy individuals and patients with noncancerous lung diseases) were analyzed using targeted, quantitative mass spectrometrybased metabolomics and used as the discovery cohort. An independent set of 216 plasma samples served as the validation cohort. Logistic regression (LR) models developed from the discovery set using ten metabolites achieved area under the receiver-operating characteristic curve (AUROC) values of 93.63%, 93.74%, and 93.91% for distinguishing all-stage, s","cbCaipdrsuBaY9m7","https://ap.wps.com/l/cbCaipdrsuBaY9m7","pdf",3309613,17,"English","# 1. Introduction\n# Abstract\n## Keywords","[{\"question\":\"What was the goal of the study?\",\"answer\":\"The study aimed to identify a robust panel of plasma metabolite markers for diagnosing early-stage non-small cell lung cancer (NSCLC).\"},{\"question\":\"How were the discovery and validation cohorts constructed?\",\"answer\":\"The discovery cohort used 680 archived plasma samples from biopsy-confirmed NSCLC patients and controls, and an independent validation cohort used 216 plasma samples.\"},{\"question\":\"What model performance did the ten-metabolite logistic regression achieve?\",\"answer\":\"Using ten metabolites, logistic regression achieved AUROC values of 93.63%, 93.74%, and 93.91% for distinguishing all-stage, stage I–II, and stage I NSCLC patients from controls, respectively.\"}]","Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection | PDF",1790161689,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22e6d54598a3c9db4eb5c736b722ba66.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1aa8849e9fc410be621e6551393a475e.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad62fe148977a8e807d8b4405d230803.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82646fb67504c65ebce16973321500f5.webp",980,692]